41 studies found for:    Open Studies | "Gastrointestinal Stromal Tumors"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Gastrointestinal Stromal Tumors"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Conditions: Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: TH-302
2 Not yet recruiting Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Advanced Gastrointestinal Stromal Tumors
Intervention: Drug: PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.
3 Recruiting A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Masitinib;   Drug: Sunitinib
4 Recruiting A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: masitinib (AB1010);   Drug: imatinib
5 Available Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (BAY73-4506)
6 Recruiting Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
7 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
8 Recruiting Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery
9 Unknown  Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Imatinib mesylate
10 Unknown  A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore
Condition: Gastrointestinal Stromal Tumors
Intervention:
11 Recruiting Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: imatinib mesylate
12 Unknown  Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
13 Recruiting Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic
Conditions: Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Endometrial Stromal Sarcoma;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Gastrointestinal Stromal Tumor;   Mast Cell Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: dasatinib;   Biological: ipilimumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
14 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
15 Recruiting Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
16 Recruiting Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
Conditions: Chronic Myeloid Leukemia;   Gastrointestinal Stromal Tumor
Intervention: Drug: Imatinib Mesylate Tablets, 400 mg
17 Recruiting MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: MEK162;   Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
18 Recruiting A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
19 Recruiting Caphosol in Oral Mucositis Due to Targeted Therapy
Conditions: Oral Mucositis;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Gastrointestinal Stromal Tumors
Interventions: Other: supersaturated calcium-phosphate rinse;   Other: sodium chloride 0.9 %
20 Not yet recruiting Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Condition: Gastro-Intestinal Stromal Tumour
Interventions: Drug: Masitinib;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years